Back to Search
NORBERT AVRIL, MD
MD
Nuclear Medicine Physician
NPI: 1952660094Individual
Specialties, Licenses & Credentials
Nuclear Medicine PhysicianPrimary
Nuclear Medicine
Code: 207U00000X
81.000110-MD(OH)
Diagnostic Radiology Physician
Radiology — Diagnostic Radiology
Code: 2085R0202X
81.000110-MD(OH)
Research & Publications (20)
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
PMID 19075273·J Clin Oncol·2009
8-other
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
PMID 19208735·Endocr Relat Cancer·2009
8-other
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
PMID 18356138·Ann Oncol·2008
4-observational
Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
PMID 18528183·Nucl Med Commun·2008
8-other
Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.
PMID 18419787·Clin Endocrinol (Oxf)·2008
4-observational
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.
PMID 18394016·Clin Endocrinol (Oxf)·2008
4-observational
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
PMID 17268018·J Nucl Med·2007
8-other
Molecular positron emission tomography and PET/CT imaging in urological malignancies.
PMID 17275167·Eur Urol·2007
6-review
Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.
PMID 17397905·Hum Pathol·2007
8-other
F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
PMID 17706529·Radiol Clin North Am·2007
6-review
Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
PMID 17208284·Gynecol Oncol·2007
8-other
Metabolic FDG-PET imaging in breast cancer: implications for treatment stratification.
PMID 17438577·Nat Clin Pract Oncol·2007
8-other
18F-FDG PET after radiofrequency ablation: Is timing everything?
PMID 16882998·J Nucl Med·2006
7-preclinical
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
PMID 16750327·Int J Radiat Oncol Biol Phys·2006
8-other
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.
PMID 16157939·J Clin Oncol·2005
8-other
Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
PMID 16203814·Clin Cancer Res·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11100 EUCLID AVE
CLEVELAND, OH 44106 - Phone
- (216) 844-3061
Quick Facts
- NPI
- 1952660094
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile